Daniel Krizay's questions to ANI Pharmaceuticals Inc (ANIP) leadership • Q2 2025
Question
Daniel Krizay, on for Vamil Divan, asked if specific medical specialties were adopting the Cortrophin prefilled syringe more rapidly than others. He also questioned whether the positive results from the ILUVIEN New Day trial had any impact on the updated 2025 guidance, potentially offsetting the negative market access challenges.
Answer
President, Director & CEO Nikhil Lalwani explained that the adoption of the prefilled syringe has been broad across all indications due to its ease of use, rather than being concentrated in any particular specialty. Regarding ILUVIEN, he acknowledged the positive feedback on the New Day study data but clarified that no specific upside from these results was factored into the revised guidance for the second half of the year.